Form 4: Interpace Biosciences Investor Ampersand 2018 Limited Partnership Exchanges Series B Preferred Stock for Series C Convertible Preferred Stock

Ampersand 2018 Limited Partnership exchanged its existing shares of Interpace Biosciences Series B Preferred Stock for newly created Series C Convertible Preferred Stock on October 11, 2024.

Summary

• On October 11, 2024, Ampersand 2018 Limited Partnership exchanged 28,000 shares of Series B Convertible Preferred Stock for 28,000 newly created shares of Series C Convertible Preferred Stock of Interpace Biosciences.
• The Series B Preferred Shares were convertible into common stock at a conversion price of $6.00 per share.
• The Series C Preferred Shares are convertible into common stock at an initial conversion price of $2.02 per share.
• The Series B Preferred Shares had no expiration date, and neither do the Series C Preferred Shares.
• Ampersand 2018 Limited Partnership holds these securities through AMP-18 Management Company Limited Partnership and AMP-18 MC LLC, which may be deemed to have beneficial ownership.
• However, Ampersand 2018 Limited Partnership, AMP-18 Management Company Limited Partnership, and AMP-18 MC LLC disclaim beneficial ownership except to the extent of their pecuniary interest.

Sentiment

Score: 5

Explanation: The document describes a routine stock conversion. It's neutral from an investment perspective unless further context suggests otherwise.

Industry Context

This exchange of preferred stock is a corporate action that may be related to Interpace Biosciences' capital structure management. Similar actions are common in the biotech industry to optimize financial flexibility and investor relations.

Key Dates

Keywords

Series C Convertible Preferred Stock, Series B Convertible Preferred Stock, Ampersand 2018 Limited Partnership, Interpace Biosciences, Conversion, Preferred Stock, IDXG